Chardan analyst Keay Nakae lowered the firm’s price target on Notable Labs to $5 from $7 and keeps a Buy rating on the shares following the Q1 report. The lower price target reflects a higher projected future share count as modeled future capital raises are expected to be more dilutive due to the decline in share price over the last quarter, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTBL:
- Notable Labs management to meet with Maxim Group
- Notable Labs Shares Strategic Insights in Business Overview
- Notable Labs price target lowered to $7 from $9 at Chardan
- Smaller Reporting Status for Notable Labs: Navigating Investor Concerns Amidst Scaled-Down Disclosure
- Notable Labs sees cash runway into 4Q24